Spero therapeutics to present at td cowen 45th annual health care conference

Cambridge, mass., feb. 25, 2025 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro) (spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (mdr) bacterial infections, today announced that esther rajavelu, spero's interim president and chief executive officer, management will present and will be available for one-on-one meetings at the td cowen 45th annual health care conference being held in boston, march 3rd – 5th, 2025.
SPRO Ratings Summary
SPRO Quant Ranking